U.S. Markets close in 3 hrs 41 mins
  • S&P 500

    3,657.30
    +71.68 (+2.00%)
     
  • Dow 30

    29,355.59
    +630.08 (+2.19%)
     
  • Nasdaq

    10,735.23
    +159.61 (+1.51%)
     
  • Russell 2000

    1,699.20
    +34.48 (+2.07%)
     
  • Crude Oil

    82.90
    +3.41 (+4.29%)
     
  • Gold

    1,701.70
    +29.70 (+1.78%)
     
  • Silver

    20.57
    +1.53 (+8.04%)
     
  • EUR/USD

    0.9810
    +0.0009 (+0.0883%)
     
  • 10-Yr Bond

    3.6190
    -0.1850 (-4.86%)
     
  • Vix

    30.31
    -1.31 (-4.14%)
     
  • GBP/USD

    1.1273
    +0.0107 (+0.9548%)
     
  • USD/JPY

    144.4840
    -0.2450 (-0.1693%)
     
  • BTC-USD

    19,386.41
    +204.89 (+1.07%)
     
  • CMC Crypto 200

    441.90
    +6.54 (+1.50%)
     
  • FTSE 100

    6,908.76
    +14.95 (+0.22%)
     
  • Nikkei 225

    26,215.79
    +278.58 (+1.07%)
     

Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

·2 min read

DUBLIN, Aug. 31, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming investor conferences:

Citi's 17th Annual BioPharma Conference on Wednesday, September 7, 2022  

  • The presentation is scheduled for 1:00 p.m. ET / 6:00 p.m. IST.

2022 Wells Fargo Healthcare Conference on Thursday, September 8, 2022

  • The presentation is scheduled for 11:00 a.m. ET / 4:00 p.m. IST.

Audio webcasts of the presentations will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Replays of the webcasts will be archived on the website for 30 days following the conferences.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.

Contacts:

Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media:

Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

 

Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)
Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-upcoming-september-investor-conferences-301615817.html

SOURCE Jazz Pharmaceuticals plc